TriangleHEALTH PROFESSIONAL · SOURCE READING
Clofarabine with or without cytarabine
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (clofarabine with or without cytarabine):
Clofarabine, a purine nucleoside analogue, was studied as a single agent in 62 patients with relapsed or refractory AML.[23]
Source links and citations
Clofarabine, a purine nucleoside analogue, was studied as a single agent in 62 patients with relapsed or refractory AML.[23]
Eight of 19 patients who received treatment for their first relapse experienced a complete response.
Clofarabine was administered in combination with intermediate-dose cytarabine in patients with relapsed or refractory AML.[24]
Source links and citations
Clofarabine was administered in combination with intermediate-dose cytarabine in patients with relapsed or refractory AML.[24]
Seven of 29 patients with AML or myelodysplastic syndrome who received treatment for their first relapse had a CR.[24][Level of evidence C3]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice